Zacks Research Downgrades Keros Therapeutics (NASDAQ:KROS) to Strong Sell

Keros Therapeutics (NASDAQ:KROS) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the company. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has an average rating of “Hold” and a consensus target price of $20.40.

Keros Therapeutics Price Performance

Shares of KROS opened at $10.22 on Wednesday. Keros Therapeutics has a one year low of $9.69 and a one year high of $22.55. The firm has a market capitalization of $202.27 million, a P/E ratio of -3.40 and a beta of 0.97. The business has a fifty day moving average of $10.73 and a 200 day moving average of $12.72.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The firm had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Analysts expect that Keros Therapeutics will post -5.19 EPS for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the sale, the director owned 9,767 shares in the company, valued at $104,702.24. This represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director directly owned 10,958 shares in the company, valued at $117,579.34. This trade represents a 19.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,425 shares of company stock valued at $89,994. Company insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in shares of Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the period. UBS Group AG raised its position in shares of Keros Therapeutics by 1.1% during the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock valued at $1,643,000 after purchasing an additional 1,091 shares during the period. Strs Ohio raised its position in shares of Keros Therapeutics by 3.9% during the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after purchasing an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. bought a new position in Keros Therapeutics in the 4th quarter worth $29,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.